Table 3.
Results of the primary and key secondary efficacy outcome measures in ubrogepant studies.
| Outcome measures | ACHIEVE I29 | ACHIEVE II30 | ||||
|---|---|---|---|---|---|---|
| Ubrogepant 50 mg |
Ubrogepant 100 mg |
Placebo | Ubrogepant 25 mg |
Ubrogepant 50 mg |
Placebo | |
| Pain free at 2 h | n=422 | n=448 | n=456 | n=435 | n=464 | n=456 |
| Number (%) | 81 (19.2) | 95 (21.2) | 54 (11.8) | 90 (20.7%) | 101 (21.8) | 65 (14.3) |
| p value | 0.002 | <0.001 | – | 0.03 | 0.01 | – |
| MBS free at 2 h | n=420 | n=448 | n=454 | n=434 | n=463 | n=456 |
| Number (%) | 162 (38.6) | 169 (37.7) | 126 (27.8) | 148 (34.1) | 180 (38.9) | 125 (27.4) |
| p value | 0.002 | 0.002 | – | 0.07 | 0.01 | – |
| Sustained pain freedom 2–24 h | n=418 | n=441 | n=452 | n=432 | n=457 | n=451 |
| Number (%) | 53 (12.7) | 68 (15.4) | 39 (8.6) | 55 (12.7) | 66 (14.4) | 37 (8.2) |
| p value | NR | 0.004 | – | NR | 0.01 | – |
MBS, most bothersome symptom (i.e. photophobia, phonophobia and nausea); NR, not reported; ODT, orally disintegrating tablet.